Related Experiment Videos
Assessment of biological responses: what to measure and when
Abstract:
During the past several years, increasing attention has been devoted to the use of biological response modifiers (BRMs) for the treatment of cancer. Phase I trials of BRMs must be designed to provide information not only regarding toxic effects, pharmacokinetics, and antitumor activities, but also on the many immunomodulatory effects. Biological monitoring must be carefully planned to enable meaningful conclusions to be drawn as to the optimal dose, schedule, and route of administration. Important considerations include selection of assays for the various biological effects, timing of testing following BRM administration, and methods for data interpretations.
Insights
Biological response modifiers (BRMs) show promise for cancer treatment. Phase I trials require careful design to assess toxicity, pharmacokinetics, and immunomodulatory effects for optimal dosing and administration.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Biological response modifiers (BRMs) are increasingly investigated for cancer therapy.
- Phase I clinical trials are crucial for evaluating novel cancer treatments.
Purpose of the Study:
- To outline essential design considerations for Phase I trials of BRMs.
- To emphasize the importance of assessing immunomodulatory effects alongside toxicity and pharmacokinetics.
Main Methods:
- Designing Phase I trials to include comprehensive assessments of BRMs.
- Implementing biological monitoring strategies to evaluate immunomodulatory effects.
- Carefully planning assay selection, testing timing, and data interpretation.
Main Results:
- Phase I trials should gather data on toxic effects, pharmacokinetics, and antitumor activities.
- Assessing immunomodulatory effects is critical for understanding BRM mechanisms.
- Optimizing dose, schedule, and route of administration requires robust biological monitoring.
Conclusions:
- Effective Phase I trial design for BRMs necessitates a multifaceted approach.
- Biological monitoring is key to drawing meaningful conclusions about BRM efficacy and safety.
- Further research should focus on refining methodologies for evaluating BRMs in clinical settings.